Annual CFI
-$44.92 M
-$74.92 M-249.72%
December 1, 2024
Summary
- As of March 12, 2025, ALDX annual cash flow from investing activities is -$44.92 million, with the most recent change of -$74.92 million (-249.72%) on December 1, 2024.
- During the last 3 years, ALDX annual CFI has fallen by -$44.91 million (-575743.59%).
- ALDX annual CFI is now -249.72% below its all-time high of $30.00 million, reached on December 31, 2023.
Performance
ALDX Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFI
-$1.56 M
-$6.83 M-129.72%
December 1, 2024
Summary
- As of March 12, 2025, ALDX quarterly cash flow from investing activities is -$1.56 million, with the most recent change of -$6.83 million (-129.72%) on December 1, 2024.
- Over the past year, ALDX quarterly CFI has dropped by -$1.56 million (-100.00%).
- ALDX quarterly CFI is now -105.21% below its all-time high of $30.00 million, reached on March 31, 2023.
Performance
ALDX Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFI
-$44.92 M
-$1.56 M-3.61%
December 1, 2024
Summary
- As of March 12, 2025, ALDX TTM cash flow from investing activities is -$44.92 million, with the most recent change of -$1.56 million (-3.61%) on December 1, 2024.
- Over the past year, ALDX TTM CFI has dropped by -$74.92 million (-249.72%).
- ALDX TTM CFI is now -159.09% below its all-time high of $76.02 million, reached on June 30, 2023.
Performance
ALDX TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Investing Formula
CFI = Cash Inflows from Investments − Cash Outflows for Investments
ALDX Cash From Investing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -249.7% | -100.0% | -249.7% |
| 3 y3 years | -10000.0% | -100.0% | -10000.0% |
| 5 y5 years | -343.1% | +63.5% | -343.1% |
ALDX Cash From Investing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -249.7% | at low | -105.2% | +97.3% | -159.1% | +40.9% |
| 5 y | 5-year | -249.7% | at low | -105.2% | +97.3% | -159.1% | +40.9% |
| alltime | all time | -249.7% | at low | -105.2% | +97.3% | -159.1% | +40.9% |
Aldeyra Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$44.92 M(-249.7%) | -$1.56 M(-129.7%) | -$44.92 M(+3.6%) |
| Sep 2024 | - | $5.26 M(-128.9%) | -$43.35 M(-10.8%) |
| Jun 2024 | - | -$18.24 M(-40.0%) | -$48.61 M(+60.0%) |
| Mar 2024 | - | -$30.38 M(<-9900.0%) | -$30.38 M(-201.3%) |
| Dec 2023 | $30.00 M(-200.2%) | $0.00(0.0%) | $30.00 M(-47.4%) |
| Sep 2023 | - | $0.00(0.0%) | $57.00 M(-25.0%) |
| Jun 2023 | - | $0.00(-100.0%) | $76.02 M(+30.9%) |
| Mar 2023 | - | $30.00 M(+11.1%) | $58.08 M(-293.9%) |
| Dec 2022 | -$29.95 M(>+9900.0%) | $27.00 M(+42.0%) | -$29.95 M(-47.4%) |
| Sep 2022 | - | $19.02 M(-206.0%) | -$56.95 M(-25.0%) |
| Jun 2022 | - | -$17.94 M(-69.1%) | -$75.97 M(+30.9%) |
| Mar 2022 | - | -$58.03 M(<-9900.0%) | -$58.03 M(>+9900.0%) |
| Dec 2021 | -$7800.00(-100.0%) | $0.00(0.0%) | -$7800.00(0.0%) |
| Sep 2021 | - | $0.00(0.0%) | -$7800.00(-100.1%) |
| Jun 2021 | - | $0.00(-100.0%) | $5.49 M(-75.9%) |
| Mar 2021 | - | -$7800.00(<-9900.0%) | $22.79 M(-21.5%) |
| Dec 2020 | $29.02 M(+57.1%) | $0.00(-100.0%) | $29.02 M(+17.3%) |
| Sep 2020 | - | $5.50 M(-68.2%) | $24.74 M(-0.7%) |
| Jun 2020 | - | $17.30 M(+178.0%) | $24.91 M(+60.4%) |
| Mar 2020 | - | $6.22 M(-245.2%) | $15.54 M(-15.9%) |
| Dec 2019 | $18.48 M(-179.2%) | -$4.29 M(-175.5%) | $18.48 M(-397.5%) |
| Sep 2019 | - | $5.68 M(-28.4%) | -$6.21 M(-47.8%) |
| Jun 2019 | - | $7.92 M(-13.6%) | -$11.91 M(-37.2%) |
| Mar 2019 | - | $9.16 M(-131.6%) | -$18.97 M(-18.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2018 | -$23.34 M(+128.8%) | -$28.97 M(>+9900.0%) | -$23.34 M(+843.5%) |
| Sep 2018 | - | -$21.30 K(-102.5%) | -$2.47 M(-59.3%) |
| Jun 2018 | - | $856.60 K(-82.2%) | -$6.08 M(-3.3%) |
| Mar 2018 | - | $4.80 M(-159.2%) | -$6.29 M(-38.3%) |
| Dec 2017 | -$10.20 M(+4428.3%) | -$8.11 M(+123.5%) | -$10.20 M(+1227.9%) |
| Sep 2017 | - | -$3.63 M(-659.4%) | -$768.00 K(-122.4%) |
| Jun 2017 | - | $648.50 K(-27.3%) | $3.43 M(+407.3%) |
| Mar 2017 | - | $891.50 K(-32.5%) | $675.50 K(-400.0%) |
| Dec 2016 | -$225.20 K(-98.3%) | $1.32 M(+132.9%) | -$225.20 K(-98.4%) |
| Sep 2016 | - | $566.70 K(-127.0%) | -$14.50 M(-4.1%) |
| Jun 2016 | - | -$2.10 M(>+9900.0%) | -$15.12 M(+15.9%) |
| Mar 2016 | - | -$9200.00(-99.9%) | -$13.04 M(+0.1%) |
| Dec 2015 | -$13.04 M(>+9900.0%) | -$12.95 M(>+9900.0%) | -$13.04 M(>+9900.0%) |
| Sep 2015 | - | -$54.20 K(+78.3%) | -$94.00 K(+104.8%) |
| Jun 2015 | - | -$30.40 K(+2071.4%) | -$45.90 K(+196.1%) |
| Mar 2015 | - | -$1400.00(-82.5%) | -$15.50 K(+9.9%) |
| Dec 2014 | -$14.10 K(<-9900.0%) | -$8000.00(+31.1%) | -$14.10 K(+131.1%) |
| Sep 2014 | - | -$6100.00(<-9900.0%) | -$6100.00(<-9900.0%) |
| Jun 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2014 | - | $0.00(0.0%) | $0.00(0.0%) |
| Dec 2013 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
| Sep 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | $0.00(0.0%) | - | - |
| Dec 2011 | $0.00 | - | - |
FAQ
- What is Aldeyra Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual CFI year-on-year change?
- What is Aldeyra Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly CFI year-on-year change?
- What is Aldeyra Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics TTM CFI year-on-year change?
What is Aldeyra Therapeutics annual cash flow from investing activities?
The current annual CFI of ALDX is -$44.92 M
What is the all time high annual CFI for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual cash flow from investing activities is $30.00 M
What is Aldeyra Therapeutics annual CFI year-on-year change?
Over the past year, ALDX annual cash flow from investing activities has changed by -$74.92 M (-249.72%)
What is Aldeyra Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of ALDX is -$1.56 M
What is the all time high quarterly CFI for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly cash flow from investing activities is $30.00 M
What is Aldeyra Therapeutics quarterly CFI year-on-year change?
Over the past year, ALDX quarterly cash flow from investing activities has changed by -$1.56 M (-100.00%)
What is Aldeyra Therapeutics TTM cash flow from investing activities?
The current TTM CFI of ALDX is -$44.92 M
What is the all time high TTM CFI for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high TTM cash flow from investing activities is $76.02 M
What is Aldeyra Therapeutics TTM CFI year-on-year change?
Over the past year, ALDX TTM cash flow from investing activities has changed by -$74.92 M (-249.72%)